ReviewFrontiers in immunology2014
Immunological Markers for PML Prediction in MS Patients Treated with Natalizumab.
Review in Frontiers in immunology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- John Cunningham Virus and Progressive Multifocal Leukoencephalopathy: A Falsely Played Diagnosis.Diseases (Basel, Switzerland) · 2024Review
- Frequent detection of IFN-gamma -producing memory effector and effector T cells in patients with progressive multifocal leukoencephalopathy.Frontiers in immunology · 2024Article
- MicroRNAs as disease progression biomarkers and therapeutic targets in experimental autoimmune encephalomyelitis model of multiple sclerosis.Neural regeneration research · 2020Review
- Biomarkers in Multiple Sclerosis.Cold Spring Harbor perspectives in medicine · 2019Review
- The miRNA Expression Profile of Experimental Autoimmune Encephalomyelitis Reveals Novel Potential Disease Biomarkers.International journal of molecular sciences · 2018Article
- Organ-specific protection mediated by cooperation between vascular and epithelial barriers.Nature reviews. Immunology · 2017Review
- Observational
- Article
- Natalizumab-induced POU2AF1/Spi-B upregulation: A possible route for PML development.Neurology(R) neuroimmunology & neuroinflammation · 2016Article
- Multiple sclerosis: genetics, biomarkers, treatments.Current opinion in neurology · 2016Review
- Diagnostic assays for polyomavirus JC and progressive multifocal leukoencephalopathy.Reviews in medical virology · 2016Review
- Rising JCV-Ab index during natalizumab therapy for MS: Inauspicious for a highly efficacious drug.Neurology(R) neuroimmunology & neuroinflammation · 2016Article
- Dimethyl fumarate treatment alters circulating T helper cell subsets in multiple sclerosis.Neurology(R) neuroimmunology & neuroinflammation · 2016Article
- Researchers Expand Focus on Progressive Forms Of Multiple Sclerosis: Efforts to Pinpoint the Beginning of Disease May Yield Clues to Treatment.P & T : a peer-reviewed journal for formulary management · 2015Article
- Drug-Induced Progressive Multifocal Leukoencephalopathy: A Comprehensive Analysis of the WHO Adverse Drug Reaction Database.CNS drugs · 2015Article
- An update on the use of natalizumab in the treatment of multiple sclerosis: appropriate patient selection and special considerations.Patient preference and adherence · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Natalizumab (NTZ), a monoclonal antibody recognizing the alpha4 integrin chain, has been approved for the treatment of active multiple sclerosis, but expose to the onset of a rare side effect, progressive multifocal leukoencephalopathy (PML). Estimating the individual risk of PML in NTZ-treated patients is a major challenge, and therapeutic strategies are mainly guided by the overall PML risk assessed by identified risk factors: JC virus (JCV) seropositivity, treatment duration (with peak incidence after 24 months), and the previous use of immunosuppressive therapies. Given that this stratification does not yet allow a precise individual prediction of PML, other predictive markers are needed, and several immunological biomarkers have been described. Quantification of anti-JCV antibody levels may improve individual predictive value, with higher baseline titers indicating increased risk. Other immunological biomarkers such as leukocyte cell membrane markers (CD49d, CD11a, and CD62L), detection of circulating JCV-specific activated T effector memory cells (TEM) or genetic screening have been proposed. In this review, we discuss how recent progress in immunology has paved the way for «new combined monitoring», which will include immunological screening, in NTZ-treated patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.